Abbott closes $21B acquisition of Exact Sciences (EXAS) at $105/share. EXAS delisted from Nasdaq on March 23, 2026, becoming ...
The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.
Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.
Exact Sciences Corp. chief Kevin T. Conroy explains what it takes to get investors to say yes. Photo: Jennifer Weiss for The ...
Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences ...
Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.
Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results